AnalystsAlbert LoweAlbert Lowe's Stock Forecasts
AnalystsAlbert Lowe
Sectors:
Industries:
Analyst Ranking
Top 35%
#1704 out of 4929 analysts
Average Return
+14.46%
Win Rate
56%5 out of 9
Risk vs Reward
Poor
Good
Albert Lowe's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Skye Bioscience IncSKYE | +104.89% | $2.25 | $4.61 | 2025-03-21 - 2025-07-03 | Buy |
Cardiff Oncology IncCRDF | +73.46% | $2.11 | $3.66 | 2024-09-06 - 2025-07-03 | Buy |
Opus Genetics IncIRD | +41.04% | $0.71 | $1.00 | 2025-04-11 - 2025-07-03 | Buy |
Lineage Cell Therapeutics IncLCTX | +16.09% | $0.87 | $1.01 | 2024-08-20 - 2025-07-03 | Buy |
Neurogene IncNGNE | +9.07% | $18.42 | $20.09 | 2025-06-17 - 2025-07-03 | Buy |
Albert Lowe Analyst Color
Get additional color on Albert Lowe's coverage of popular stocks
Albert Lowe's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Neurogene IncNGNE | 1 | Buy | $50.00 | +148.88% | Initiates Coverage On | 19 days ago |
Atossa Therapeutics IncATOS | 1 | Buy | $4.00 | +371.14% | Initiates Coverage On | a month ago |
Opus Genetics IncIRD | 1 | Buy | $6.00 | +500.00% | Initiates Coverage On | 3 months ago |
Skye Bioscience IncSKYE | 2 | Buy | $14.00 | +203.69% | Maintains | 3 months ago |
Sab Biotherapeutics IncSABS | 1 | Buy | $11.00 | +539.53% | Initiates Coverage On | 9 months ago |
Cardiff Oncology IncCRDF | 1 | Buy | $8.00 | +118.58% | Initiates Coverage On | 10 months ago |
Lineage Cell Therapeutics IncLCTX | 1 | Buy | $4.00 | +296.04% | Initiates Coverage On | a year ago |
Pmv Pharmaceuticals IncPMVP | 1 | Buy | $6.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.